Drug Repurposing Approaches: Existing Leads for Novel Threats and Drug Targets
- 21 May 2021
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Protein & Peptide Science
- Vol. 22 (3) , 251-271
Abstract
Drug Repurposing (DR) is an alternative to the traditional drug discovery process. It is cost and time effective,with high returns and low-risk process that can tackle the increasing need for interventions for varied diseases and new outbreaks. Repurposing of old drugs for other diseases has gained wider attention, as there have been several old drugs approved by the FDA for new diseases. In the global emergency of COVID-19 pandemic, this is one of the strategies implemented in the repurposing of old anti-infective, anti-rheumatic and anti-thrombotic drugs. The goal of the current review is to elaborate the process of DR, its advantages, repurposed drugs for a plethora of disorders, and the evolution of related academic publications. Further, detailed are the computational approaches: literature mining and semantic inference, network-based drug repositioning, signature matching, retrospective clinical analysis, molecular docking and experimental phenotypic screening. We discuss the legal and economic potential barriers in DR, existent collaborative models and recommendations for overcoming these hurdles and leveraging the complete potential of DR in finding new indications.Keywords
This publication has 61 references indexed in Scilit:
- Open-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseasesDrug Design, Development and Therapy, 2013
- A Semi-Supervised Method for Drug-Target Interaction Prediction with Consistency in NetworksPLOS ONE, 2013
- A network flow approach to predict drug targets from microarray data, disease genes and interactome network - case study on prostate cancerJournal of Clinical Bioinformatics, 2012
- Predicting selective drug targets in cancer through metabolic networksMolecular Systems Biology, 2011
- Two-stage flux balance analysis of metabolic networks for drug target identificationBMC Systems Biology, 2011
- Semi-supervised drug-protein interaction prediction from heterogeneous biological spacesBMC Systems Biology, 2010
- Prediction of drug–target interaction networks from the integration of chemical and genomic spacesBioinformatics, 2008
- Non-steroidal anti-inflammatory drugs suppress the ERK signaling pathway via block of Ras/c-Raf interaction and activation of MAP kinase phosphatasesCellular Signalling, 2008
- Can the pharmaceutical industry reduce attrition rates?Nature Reviews Drug Discovery, 2004
- ANTI-METASTATIC EFFECT OF ASPIRINThe Lancet, 1972